For example, lung-restricted NRF2E79Q expression in p53;p16-deficient background promotes in situ small cell lung cancer (SCLC) lesions but undergoes silencing in large aggressive SCLC tumors (21). Here, TP53 is linked to small cell lung carcinoma.